Search results for " CALMET"

showing 5 items of 15 documents

A prospective observational study on oral administration of Ellagic Acid and Annona Muricata in patients affected by non-muscle invasive bladder canc…

2021

Introduction: BCG and MMC shortage and Covid-19 pandemic, more recently, limit accessibility to maintenance regimen in intravesical prophylaxis against recurrence of non-muscle invasive bladder cancer (NMIBC). Ellagic acid (EA) and Annona muricata (AM) exert antitumor activity against different human tumours. An observational prospective study on the prophylactic effect of oral administration of EA+AM in patients avoiding maintenance regimen is presented. Materials and methods: Patients affected by NMIBC and not undergoing maintenance after a 6-week course of intravesical prophylaxis with MMC or BCG were entered. Tis and very high-risk tumours were excluded. After informed consent, the pati…

bladder carcinomamedicine.medical_specialtybacillus calmette-guerinmedicine.medical_treatment030232 urology & nephrologyAdministration Oralnutraceuticsintravesical instillationGastroenterologyAnnonalaw.inventionannona muricata03 medical and health sciences0302 clinical medicineAdjuvants ImmunologicRandomized controlled trialellagic acidOral administrationlawInternal medicineCytologymedicineHumansNeoplasm InvasivenessProspective StudiesProspective cohort studyPandemicsChemotherapyBladder cancermedicine.diagnostic_testSARS-CoV-2business.industryCOVID-19General MedicineCystoscopymedicine.diseaseRegimenAdministration IntravesicalUrinary Bladder Neoplasms030220 oncology & carcinogenesisBCG VaccineNeoplasm Recurrence Localbusinessannona muricata; bacillus calmette-guerin; bladder carcinoma; ellagic acid; intravesical instillation; nutraceuticsUrologia Journal
researchProduct

A Case of Epididymo-orchitis after intravesical bacille Calmette-Guérin therapy for superficial bladder carcinoma in a patient with latent tuberculos…

2016

Background: Intravesical instillation of bacille Calmette-Guérin (BCG) has been established as efficient therapy for superficial bladder carcinoma. Overall, intravesical BCG is well tolerated and results in complications of less than 5 %. However, adverse effects such as granulomatous prostatitis, pneumonitis, hepatitis, sepsis, and hypersensitivity reactions may occur. The reported rate for tuberculous orchitis after BCG intravesical therapy is 0.4 %. Findings: We report a case of monolateral tuberculous orchitis occurring one month after the second course of intravescical instillation of bacille Calmette-Guérin in a patient with proven superficial bladder carcinoma and latent tuberculosis…

medicine.medical_specialtyCancer ResearchComplicationsSettore MED/17 - Malattie InfettiveEpidemiologyBladder030232 urology & nephrologyUrologyShort ReportInfectious DiseaseGastroenterologySepsis03 medical and health sciences0302 clinical medicineInternal medicinemedicineGranulomatous prostatitisBladder; Calmette; Complications; Guérin; Intravesical; Infectious Diseases; Oncology; Epidemiology; Cancer ResearchPneumonitisHepatitisLatent tuberculosisbusiness.industryIntravesicalIsoniazidmedicine.diseaseInfectious DiseasesOncology030220 oncology & carcinogenesisOrchitisSuperficial Bladder CarcinomabusinessComplicationGuérinmedicine.drugCalmetteInfectious Agents and Cancer
researchProduct

Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell…

1996

Objectives. To evaluate a selected population of 50 consecutive patients with primary T1, G3 bladder transitional cell carcinoma in the absence of carcinoma in situ (Tis) treated with a bladder-sparing approach. Methods. Between January 1983 and December 1992, all patients were treated by transurethral resection (TUR) plus adjuvant intravesical chemotherapy over 1 year. In most cases, doxorubicin, epirubicin, and mitomycin were used alone or in combination. Results. At a mean follow-up period of 52 months (range, 18 to 126), 16 of 50 patients (32%) showed a recurrent superficial tumor. The recurrent lesion was of Stage T1 in 11 (22%) cases, but was a T1, G3 tumor only in 5 cases (10%). In 2…

medicine.medical_specialtyUrologymedicine.medical_treatmentPopulationAntineoplastic AgentsMitomycinsSettore MED/24 - UrologiaCystectomyUrethraCarcinomamedicineHumansBACILLUS CALMETTE-GUERINeducationEpirubicinNeoplasm StagingCarcinoma Transitional Celleducation.field_of_studyUrinary bladderBladder cancerbusiness.industryCarcinoma in situmedicine.diseaseCombined Modality TherapyCANCERSurgeryAdministration Intravesicalmedicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsChemotherapy AdjuvantDoxorubicinSurgical Procedures OperativeNeoplasm Recurrence LocalbusinessFollow-Up StudiesEpirubicinmedicine.drugUrology
researchProduct

Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy

2015

Context: The therapeutic strategy in intermediate risk (IR) non-muscle invasive bladder cancer (NMIBC) recurring after intravesical therapy (IT) is not well defined. Most patients are usually retreated by Bacillus Calmette-Guerin (BCG). Aims: To evaluate the efficacy of intravesical chemotherapy (ICH) given at recurrence after the first cycle of ICH in IR-NMIBC recurring 6 months or later. Settings and Design: Retrospective analysis of the efficacy of ICH given after previous IT. Materials and Methods: The clinical files of IR-NMIBC patients recurring later than 6 months after transurethral resection (TUR) and IT and retreated by IT were reviewed. The patients should be at intermediate risk…

medicine.medical_specialtyrecurrenceUrologyContext (language use)intermediate risklcsh:RC870-923Settore MED/24 - UrologiaCytologyintravesical chemotherapyAdjuvant therapyMedicinecardiovascular diseasesBacillus Calmette-GuerinBladder cancermedicine.diagnostic_testbusiness.industryProportional hazards modelCystoscopylcsh:Diseases of the genitourinary system. Urologymedicine.diseaseSurgerynervous system diseasesBacillus Calmette-Guerin intermediate risk intravesical chemotherapy non muscle invasive bladder cancer recurrenceMann–Whitney U testnon muscle invasive bladder cancerOriginal ArticlebusinessIntravesical chemotherapyUrology Annals
researchProduct

MELCOR per lo Studio Integrale di Sequenze Incidentali su Reattori PWR da 900 MWe e valutazioni preliminari d'impatto a breve e medio raggio

2014

Il presente documento è stato preparato nel corso della seconda annualità dell'AdP ENEA-MSE nell'ambito dell'obiettivo B-Task B_1 (Sviluppo di una Metodologia per Valutazioni di Sicurezza in Condizioni Incidentali o di Pre-Emergenza) della Linea Progettuale 1 (Sviluppo competenze scientifiche nel campo della sicurezza nucleare). Esso riporta i principali risultati della simulazione MELCOR di un transitorio del tipo “short term Station Blackout (SBO)” con possibile rottura dei tubi a U del GV (Steam Generator Tube Rupture - SGTR) indotta da stress termici e un lavoro preliminare di raccolta di informazioni sulle potenzialità presentate da alcune piattaforma di simulazione ad oggi utilizzate …

simulazione MELCOR calpuff calmet frames MM5Settore ING-IND/19 - Impianti Nucleari
researchProduct